Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Zacks Investment Research

08 Jul 2026, 14:55 UTC · 2h ago

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

What the story claims

3 claims · each scored for market impact

What matters in this story

1
The mean analyst price target for Nuvectis Pharma (NVCT) is $31, representing a potential 61.5% upside from its last close of $19.2. — A high consensus price target can attract bullish momentum and buying pressure for a small-cap stock.
+0.40
2
Analysts have shown strong agreement in revising earnings estimates upward for Nuvectis Pharma. — Positive earnings revisions are typically a strong fundamental signal for future price appreciation.
+0.30
3
Nuvectis Pharma shares gained 95.9% over the previous four-week period. — While positive, this is historical performance rather than a forward-looking catalyst.
+0.10

Which stocks this story touches

How each ticker is affected

6 related stories

Zacks Investment Research
2h ago
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know
- analyst estimates
- equity research
- price targets
Read

Wall Street Analysts See… — NVCT +0.80 | NewsImpactScreener

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

What matters in this story

How each ticker is affected

Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

What matters in this story

How each ticker is affected

Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Wall Street Analysts Predict a 25.33% Upside in Entegris (ENTG): Here's What You Should Know

Does GXO Logistics (GXO) Have the Potential to Rally 36.13% as Wall Street Analysts Expect?

MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?

Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?

Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

What matters in this story

How each ticker is affected

Next reads from the same story arc

Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

What matters in this story

How each ticker is affected

Next reads from the same story arc

Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Wall Street Analysts Predict a 25.33% Upside in Entegris (ENTG): Here's What You Should Know

Does GXO Logistics (GXO) Have the Potential to Rally 36.13% as Wall Street Analysts Expect?

MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?

Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?

Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.